Fewer injections result in fewer injection-related adverse events

• In a Phase 3b clinical study evaluating the incidence of injection-related adverse events, (NYSE:TEVA +0.1%) finds that three-times-per-week injections of Copaxone 40 mg resulted in a 50% reduction in such events compared to daily injections of Copaxone 20 mg.
• The number of injections was reduced 57% (3 days vs. 7 days) and the number of injection-related adverse events was reduced 50%. The results certainly appear predictable.